Retatrutide 60mg Pen – Advanced Triple-Receptor Research

Retatrutide 60mg Pen is a research-format product containing retatrutide, also known by the development code LY3437943. Retatrutide is an investigational peptide designed to activate three metabolically important hormone receptors: GLP-1, GIP, and glucagon receptors.

This three-receptor mechanism distinguishes retatrutide from earlier incretin-based compounds that primarily target one or two receptor systems.

Research into Retatrutide 60mg Pen is focused on understanding how simultaneous activation of GLP-1, GIP, and glucagon signalling may influence appetite regulation, glucose metabolism, energy balance, substrate utilization and body-weight biology.

Retatrutide has attracted substantial scientific interest because clinical studies have produced significant metabolic effects. In the 2023 Phase 2 trial published in the New England Journal of Medicine, participants receiving the highest studied retatrutide regimen experienced a mean 24.2% reduction in body weight after 48 weeks. The trial also reported dose-related gastrointestinal adverse events and transient increases in heart rate.

Since then, the clinical research program has advanced into Phase 3. In 2026, Eli Lilly reported positive topline results from multiple TRIUMPH trials, including substantial weight reductions in several study populations. Retatrutide nevertheless remains investigational and has not been approved by a regulatory agency.

What Is Retatrutide?

Retatrutide is a synthetic peptide being investigated as a triple hormone receptor agonist.

Its three primary molecular targets are:

• GLP-1 receptor
• GIP receptor
• Glucagon receptor

The compound is sometimes described as a GIP/GLP-1/glucagon receptor agonist because all three pathways are incorporated into its pharmacological profile.

This distinguishes retatrutide from:

• Semaglutide, which primarily targets GLP-1 receptors
• Tirzepatide, which targets GIP and GLP-1 receptors
• Retatrutide, which targets GIP, GLP-1 and glucagon receptors

The scientific rationale behind this combination is that these hormone pathways participate in different aspects of energy homeostasis and metabolic regulation.

Researchers are therefore studying whether coordinated activation of the three pathways can produce a broader biological response than activation of one or two pathways alone.

What Does Retatrutide 60mg Pen Mean?

The Retatrutide 60mg Pen designation describes the stated quantity and format of the research product.

The 60mg specification refers to the labelled amount of retatrutide associated with the product.

The Pen designation refers to the product’s pen-based presentation.

Importantly, the labelled 60mg quantity should not be interpreted as an approved clinical dose or as evidence that the product corresponds to an approved pharmaceutical presentation.

Retatrutide remains investigational. Lilly specifically warns that products claiming to contain retatrutide outside Lilly-sponsored clinical trials may contain incorrect amounts, contaminants, impurities or even different ingredients.

For laboratory research, researchers should therefore distinguish carefully between the research-format product and the investigational pharmaceutical candidate being evaluated in controlled clinical trials.

The Three Receptors Targeted by Retatrutide

The central feature of Retatrutide 60mg Pen research is its triple-receptor mechanism.

GLP-1 Receptor

GLP-1 is an incretin hormone involved in glucose-dependent insulin signalling, appetite regulation and gastrointestinal processes.

GLP-1 receptor signalling is therefore widely studied in metabolic research.

Researchers investigating retatrutide can examine how GLP-1 receptor activation contributes to the overall response generated by the molecule.

GIP Receptor

GIP, or glucose-dependent insulinotropic polypeptide, is another incretin hormone.

GIP participates in nutrient-related endocrine signalling and insulin-related physiology.

Retatrutide’s GIP receptor activity provides another layer of metabolic signalling that distinguishes it from compounds acting exclusively through GLP-1.

Glucagon Receptor

Glucagon has an important role in energy metabolism.

Glucagon receptor activation has been studied in relation to hepatic metabolism, substrate utilization and energy expenditure.

The inclusion of glucagon receptor activity is one of the most distinctive aspects of retatrutide research.

Why Is Retatrutide Called a Triple Agonist?

A receptor agonist is a compound capable of activating a receptor.

Retatrutide is described as a triple agonist because it has activity at three receptor systems:

GIP + GLP-1 + glucagon

This is fundamentally different from simply combining three separate compounds.

Retatrutide is a single molecular entity designed to interact with all three receptor targets.

That makes it an interesting model for researchers investigating multi-receptor pharmacology.

How Does Retatrutide Work?

The biological effects of retatrutide arise from its interaction with three G-protein-coupled receptor systems.

Each receptor can initiate intracellular signalling pathways.

The combined activity creates a complex pharmacological profile involving:

• Appetite-related signalling
• Glucose-related pathways
• Insulin signalling
• Hepatic metabolism
• Energy expenditure
• Nutrient sensing
• Lipid metabolism
• Substrate utilization

The precise contribution of each receptor pathway remains an active area of research.

Rather than considering retatrutide as simply a stronger version of a GLP-1 compound, researchers are interested in understanding how three distinct receptor pathways interact within the same molecular framework.

Retatrutide and Appetite Signalling

Appetite regulation involves a complex network involving the brain, gastrointestinal tract, endocrine hormones and metabolic signals.

GLP-1 signalling is known to participate in appetite-related pathways, while GIP and glucagon can also contribute to broader metabolic communication.

Research involving Retatrutide 60mg Pen therefore includes investigation into how simultaneous receptor activation affects:

• Food intake
• Appetite-related signalling
• Satiety pathways
• Nutrient sensing
• Energy balance
• Metabolic adaptation

These effects are studied in controlled experimental and clinical research environments.

Retatrutide and Energy Balance

Energy balance is determined by the relationship between energy intake and energy expenditure.

The three receptors targeted by retatrutide have biological roles relevant to this relationship.

GLP-1 signalling can influence appetite-related pathways.

GIP participates in nutrient and endocrine signalling.

Glucagon is involved in metabolic processes associated with energy availability and substrate utilization.

The combination makes retatrutide particularly interesting for researchers studying how multiple endocrine signals interact to regulate energy balance.

Retatrutide and Glucose Metabolism

Glucose metabolism is another major area of retatrutide research.

GLP-1 and GIP are incretin hormones with important relationships to glucose-dependent insulin secretion.

Glucagon also plays a major role in maintaining glucose availability.

Because retatrutide activates all three receptor systems, researchers can investigate the interaction between these pathways within a single molecular model.

Research areas include:

• Glucose regulation
• Insulin signalling
• Glucagon signalling
• Hepatic glucose metabolism
• Incretin biology
• Glycemic control
• Metabolic adaptation

Retatrutide and Lipid Metabolism

Retatrutide research also extends beyond glucose.

The glucagon receptor component is particularly relevant to investigations involving energy substrate utilization and lipid metabolism.

Researchers are interested in whether combined GIP, GLP-1 and glucagon signalling produces changes in metabolic substrate handling that differ from single- or dual-receptor agonism.

This provides opportunities to investigate:

• Fatty-acid metabolism
• Lipid oxidation
• Hepatic lipid pathways
• Adipose tissue signalling
• Energy substrate selection
• Metabolic flexibility

Retatrutide and Body-Weight Research

Body weight regulation is one of the most extensively investigated areas involving retatrutide.

In the Phase 2 obesity trial, the highest studied retatrutide group had a least-squares mean body-weight change of −24.2% at 48 weeks, compared with −2.1% for placebo.

More recently, Lilly reported Phase 3 results from TRIUMPH-1 showing an average 28.3% weight reduction at 80 weeks among participants receiving the 12mg investigational regimen.

These results have generated substantial scientific interest in multi-receptor approaches to metabolic research.

However, clinical trial outcomes should not be interpreted as guaranteed results from a research-format product.

Updated Retatrutide Research: Phase 3

Retatrutide research has progressed substantially beyond the original Phase 2 studies.

In May 2026, Lilly reported topline results from TRIUMPH-1. Participants receiving the 12mg investigational regimen experienced an average 28.3% body-weight reduction at 80 weeks, while 45.3% achieved at least 30% weight reduction.

In July 2026, Lilly reported additional Phase 3 results from TRIUMPH-2 and TRIUMPH-3.

TRIUMPH-2 evaluated adults with obesity or overweight and type 2 diabetes. The highest studied regimen produced an average 20.8% weight reduction at 80 weeks.

TRIUMPH-3 evaluated participants with severe obesity and established cardiovascular disease, with or without type 2 diabetes. The highest studied regimen produced an average 22.6% weight reduction at 80 weeks.

These are investigational clinical-trial results and do not establish that an independently supplied Retatrutide 60mg Pen will reproduce those findings.

Retatrutide Compared With Semaglutide

Semaglutide primarily activates the GLP-1 receptor.

Retatrutide activates GLP-1, GIP and glucagon receptors.

This makes the compounds mechanistically different.

Compound	Primary Receptor Targets	Research Interest
Semaglutide	GLP-1	Incretin signalling, appetite and glucose biology
Tirzepatide	GIP + GLP-1	Dual incretin signalling and metabolic research
Retatrutide	GIP + GLP-1 + glucagon	Triple-receptor metabolic signalling

This comparison is useful because it illustrates how metabolic research has progressed from single-receptor agonism toward increasingly complex multi-receptor approaches.

Retatrutide Compared With Tirzepatide

Tirzepatide is a dual GIP/GLP-1 receptor agonist.

Retatrutide adds glucagon receptor activity.

The difference can be summarized as:

Tirzepatide: GIP + GLP-1

Retatrutide: GIP + GLP-1 + glucagon

The additional glucagon component is one of the reasons researchers are interested in retatrutide’s effects on energy expenditure and substrate utilization.

Lilly is also conducting comparative Phase 3 research involving retatrutide and tirzepatide, including the TRIUMPH-5 study.

Retatrutide and Metabolic Flexibility

Metabolic flexibility describes the ability of biological systems to adapt substrate utilization according to nutritional and energetic conditions.

Because retatrutide activates three metabolically relevant receptor systems, it provides an interesting research model for studying metabolic flexibility.

Laboratory research may examine:

• Glucose utilization
• Fatty-acid utilization
• Hepatic metabolism
• Adipose tissue signalling
• Energy expenditure
• Nutrient availability
• Hormonal communication

These pathways can be studied independently or together to understand the broader metabolic response.

Retatrutide and Endocrine Signalling

Retatrutide research is fundamentally endocrine research.

The three receptor targets belong to hormone signalling systems that communicate information about nutrient availability and energy status.

The compound therefore provides researchers with an opportunity to study how multiple endocrine pathways can be activated simultaneously.

This can be particularly valuable in:

• Receptor pharmacology
• Metabolic biology
• Endocrinology
• Cellular signalling
• Nutrient sensing
• Hormone-receptor research

Retatrutide Research and Gastrointestinal Biology

GLP-1 receptor signalling is closely connected with gastrointestinal physiology.

Research involving retatrutide therefore includes investigation into gastrointestinal responses associated with incretin signalling.

In the Phase 2 clinical trial, gastrointestinal adverse events were among the most frequently reported adverse events and were generally mild to moderate. The frequency was dose-related.

This is an important part of the research profile because gastrointestinal biology can influence both metabolic signalling and tolerability.

Retatrutide and Heart-Rate Research

The Phase 2 trial also observed dose-dependent increases in heart rate that peaked around week 24 and subsequently declined.

This finding illustrates why receptor pharmacology should be evaluated across multiple physiological systems rather than focusing exclusively on body-weight outcomes.

Retatrutide research therefore includes broader safety and physiological observation alongside metabolic endpoints.

Retatrutide 60mg Pen Format

The Retatrutide 60mg Pen uses a pen-based presentation rather than a conventional dry-powder vial format.

The product format can be relevant to laboratories that require standardized product presentation and convenient inventory management.

However, the exact formulation, concentration, excipients, container characteristics and stability profile should be verified using the product’s batch-specific documentation.

The presence of a pen format does not establish that the product is an approved pharmaceutical device or formulation.

Storage and Handling

The Retatrutide 60mg Pen should be maintained according to the product-specific storage documentation.

Research peptide formulations can be sensitive to environmental conditions, including temperature, light and physical handling.

Good laboratory practice includes:

• Maintaining appropriate temperature conditions
• Protecting the product from excessive heat
• Limiting unnecessary exposure to direct light
• Maintaining container integrity
• Following documented storage requirements
• Recording lot and batch information
• Monitoring expiration or retest dates

Researchers should always follow the storage requirements supplied for the specific product rather than assuming that all retatrutide-containing materials have identical stability characteristics.

Quality Control for Retatrutide Research

Quality control is particularly important for investigational peptide materials.

Researchers may consider documentation covering:

Identity

Confirmation that the material corresponds to the stated research compound.

Purity

Analytical purity can be important when the material is being used in sensitive experimental systems.

Quantity

The labelled amount should correspond with the product documentation.

Batch Traceability

A unique lot or batch number supports reproducibility.

Analytical Testing

Depending on the intended application, analytical methods may include chromatographic, spectrometric or other peptide-characterization techniques.

Storage History

Temperature and handling history can be relevant to peptide stability.

Retatrutide and Research Reproducibility

Reproducibility is particularly important when studying receptor-active compounds.

A researcher’s observations can be influenced by:

• Compound identity
• Purity
• Concentration
• Experimental model
• Exposure conditions
• Receptor expression
• Biological variability
• Storage conditions
• Analytical methodology

The Retatrutide 60mg Pen should therefore be documented carefully as part of any research workflow.

Retatrutide in Comparative Pharmacology

Retatrutide provides an interesting compound for comparative pharmacology.

Researchers can compare triple-receptor activity against:

• GLP-1 receptor agonists
• GIP/GLP-1 dual agonists
• Glucagon receptor agonists
• Other metabolic peptides
• Native hormone systems

These comparisons can help researchers understand whether combining receptor activity changes downstream biological responses.

Retatrutide and Multi-Receptor Drug Design

Retatrutide also represents a broader development trend in metabolic pharmacology: designing molecules capable of interacting with multiple hormone receptors.

Traditional pharmacology often focused on highly selective activity at a single target.

Multi-receptor agonists take a different approach.

By incorporating activity at several related pathways, researchers can investigate whether complementary biological mechanisms produce a broader metabolic response.

Retatrutide is currently one of the most prominent examples of this approach.

Retatrutide 60mg Pen Research Applications

Potential research areas include:

Metabolic Research

Investigating glucose, lipid and energy metabolism.

Receptor Biology

Studying GLP-1, GIP and glucagon receptor signalling.

Endocrine Research

Examining interactions between nutrient-stimulated hormones.

Appetite Biology

Investigating pathways involved in appetite and energy intake.

Energy Expenditure

Studying metabolic pathways associated with energy utilization.

Cellular Signalling

Examining downstream pathways activated by G-protein-coupled receptors.

Comparative Pharmacology

Comparing triple-receptor activity with single- and dual-receptor compounds.

Obesity Research

Studying the biological mechanisms underlying body-weight regulation.

Retatrutide 60mg Pen Specifications

Product Name: Retatrutide 60mg Pen

Research Compound: Retatrutide

Development Code: LY3437943

Primary Targets: GLP-1 receptor, GIP receptor and glucagon receptor

Product Format: Pen-based research formulation

Labelled Quantity: 60mg

Research Category: Investigational metabolic peptide

Primary Research Areas: Metabolic signalling, endocrine biology, receptor pharmacology and energy-balance research

Intended Use: Research and laboratory investigation only

Important: Exact formulation, concentration, excipients, stability specifications and storage requirements should be verified against the batch-specific product documentation.

Frequently Asked Questions

What is Retatrutide 60mg Pen?

Retatrutide 60mg Pen is a research-format product containing retatrutide, an investigational triple receptor agonist targeting GLP-1, GIP and glucagon receptors.

What is retatrutide also called?

Retatrutide is also known by the development code LY3437943.

What receptors does retatrutide target?

Retatrutide activates the GLP-1, GIP and glucagon receptors.

Why is retatrutide called a triple agonist?

It is called a triple agonist because one molecule has activity at three hormone receptor systems rather than only one or two.

How is retatrutide different from semaglutide?

Semaglutide primarily targets GLP-1 receptors, whereas retatrutide targets GLP-1, GIP and glucagon receptors.

How is retatrutide different from tirzepatide?

Tirzepatide targets GIP and GLP-1 receptors. Retatrutide additionally targets the glucagon receptor.

Has retatrutide been studied in clinical trials?

Yes. Retatrutide has progressed through Phase 2 and multiple Phase 3 clinical trials. The original Phase 2 obesity trial was published in the New England Journal of Medicine, and Lilly reported additional Phase 3 topline results in 2026.

Is retatrutide approved?

No. As of September 2026, Lilly states that retatrutide has not been approved by any regulatory agency.

Is Retatrutide 60mg Pen the same as an approved medicine?

No approved retatrutide medicine currently exists. A research-format Retatrutide 60mg Pen should not be represented as an approved pharmaceutical product.

What does 60mg mean?

60mg refers to the labelled quantity of retatrutide associated with the research product. It should not be interpreted as an approved clinical dosing recommendation.

What research areas are associated with retatrutide?

Research areas include GLP-1, GIP and glucagon receptor biology, appetite signalling, glucose metabolism, energy balance, lipid metabolism, endocrine communication and metabolic pharmacology.

How should Retatrutide 60mg Pen be stored?

Storage should follow the exact product-specific documentation supplied with the material. Researchers should avoid assuming that storage requirements are identical across different retatrutide formulations.

Why is retatrutide important in metabolic research?

Retatrutide is important because it provides a single-molecule model for studying simultaneous GLP-1, GIP and glucagon receptor activation.

Research Status and Regulatory Considerations

Retatrutide remains an investigational compound.

Lilly’s current public information specifically states that retatrutide has not been approved by any regulatory agency and warns against products claiming to contain retatrutide outside Lilly-sponsored clinical trials.

This distinction is essential when discussing a Retatrutide 60mg Pen.

Clinical trial results involving Lilly’s investigational material should not automatically be interpreted as validation of every commercially available product labelled “retatrutide.”

Research materials can differ substantially in:

• Manufacturing source
• Purity
• Identity
• Formulation
• Concentration
• Stability
• Container system
• Quality controls

Researchers should therefore evaluate each material according to its own documentation.

Responsible Research Use

The Retatrutide 60mg Pen should be treated as a research material and handled within an appropriate laboratory framework.

Retatrutide has substantial biological activity, and clinical research continues to evaluate its safety and pharmacological effects.

The existence of positive clinical-trial findings does not remove the investigational status of the compound.

Researchers should therefore avoid extrapolating clinical-trial results directly to independently sourced research materials.

Important Research Disclaimer

Retatrutide 60mg Pen is intended for laboratory research and analytical purposes only. It is not an approved medicine and is not intended to diagnose, treat, cure or prevent any disease or medical condition.

This product information is provided for scientific and research context only. It should not be interpreted as medical advice, treatment guidance, dosing instructions or instructions for administration to humans or animals.

Researchers should review applicable product documentation, safety information, institutional procedures and regulatory requirements before working with investigational receptor-active compounds.

Conclusion

Retatrutide 60mg Pen represents a research-format presentation of retatrutide, an investigational peptide designed to activate three major metabolic hormone receptors: GLP-1, GIP and glucagon.

Its triple-receptor mechanism distinguishes retatrutide from single-pathway GLP-1 agonists and dual GIP/GLP-1 agonists.

Research has examined retatrutide across a wide range of metabolic questions, including appetite signalling, glucose regulation, energy balance, substrate utilization, endocrine communication and body-weight biology.

The scientific interest surrounding retatrutide has continued to grow as the compound has progressed from Phase 2 into a broad Phase 3 clinical development program. The original Phase 2 study reported substantial weight reductions over 48 weeks, while 2026 Phase 3 reports have provided additional evidence of significant metabolic effects in several study populations.

For laboratory researchers, the most distinctive feature of Retatrutide 60mg Pen is its multi-receptor pharmacology. Studying GLP-1, GIP and glucagon activity together can provide insight into how interconnected endocrine pathways influence metabolism and energy homeostasis.

However, retatrutide remains investigational and is not currently approved by any regulatory agency. Research-format products should therefore be clearly distinguished from pharmaceutical products used within controlled clinical trials.

For Research Use Only. Not for human or veterinary use.

Retatrutide 60mg Pen Retatrutide 60mg Pen Retatrutide 60mg Pen Retatrutide 60mg Pen  Retatrutide 60mg Pen Retatrutide 60mg Pen Retatrutide 60mg Pen Retatrutide 60mg Pen Retatrutide 60mg Pen Retatrutide 60mg Pen Retatrutide 60mg Pen Retatrutide 60mg Pen Retatrutide 60mg Pen Retatrutide 60mg Pen Retatrutide 60mg Pen Retatrutide 60mg Pen Retatrutide 60mg Pen Retatrutide 60mg Pen Retatrutide 60mg Pen Retatrutide 60mg Pen